MX2023014530A - Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo. - Google Patents

Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo.

Info

Publication number
MX2023014530A
MX2023014530A MX2023014530A MX2023014530A MX2023014530A MX 2023014530 A MX2023014530 A MX 2023014530A MX 2023014530 A MX2023014530 A MX 2023014530A MX 2023014530 A MX2023014530 A MX 2023014530A MX 2023014530 A MX2023014530 A MX 2023014530A
Authority
MX
Mexico
Prior art keywords
nitroxoline
treatment
cutaneous neurofibroma
neurofibroma
cutaneous
Prior art date
Application number
MX2023014530A
Other languages
English (en)
Spanish (es)
Inventor
David Brown
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of MX2023014530A publication Critical patent/MX2023014530A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023014530A 2021-06-09 2022-06-09 Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo. MX2023014530A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108224.3A GB202108224D0 (en) 2021-06-09 2021-06-09 Treatment
PCT/GB2022/051442 WO2022258972A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma

Publications (1)

Publication Number Publication Date
MX2023014530A true MX2023014530A (es) 2024-04-10

Family

ID=76838879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014530A MX2023014530A (es) 2021-06-09 2022-06-09 Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo.

Country Status (12)

Country Link
US (1) US20240261276A1 (enExample)
EP (1) EP4351576A1 (enExample)
JP (1) JP2024520690A (enExample)
KR (1) KR20240024175A (enExample)
CN (1) CN117769419A (enExample)
AU (1) AU2022290019A1 (enExample)
BR (1) BR112023025789A2 (enExample)
CA (1) CA3221964A1 (enExample)
GB (1) GB202108224D0 (enExample)
IL (1) IL309177A (enExample)
MX (1) MX2023014530A (enExample)
WO (1) WO2022258972A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202116743D0 (en) * 2021-11-19 2022-01-05 Healx Ltd Treatment
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970128B1 (en) * 2013-03-15 2019-12-04 Asieris Pharmaceutical Technologies Co., Ltd. Base addition salts of nitroxoline and uses thereof
CA3287905A1 (en) * 2016-10-14 2025-11-29 Wake Forest University Health Sciences Compositions, cell constructs, and methods of making and using the same
EP3883552B1 (en) * 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN112402388A (zh) * 2019-08-05 2021-02-26 江苏亚虹医药科技股份有限公司 一种用于治疗膀胱癌的口服固体制剂及其制备方法

Also Published As

Publication number Publication date
US20240261276A1 (en) 2024-08-08
JP2024520690A (ja) 2024-05-24
BR112023025789A2 (pt) 2024-02-27
CA3221964A1 (en) 2022-12-15
WO2022258972A1 (en) 2022-12-15
CN117769419A (zh) 2024-03-26
EP4351576A1 (en) 2024-04-17
AU2022290019A1 (en) 2023-12-14
IL309177A (en) 2024-02-01
KR20240024175A (ko) 2024-02-23
GB202108224D0 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
GEAP202315746A (en) Protein tyrosine phosphatase inhibitors
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MY208632A (en) Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
MX2025009723A (es) Metodos de tratamiento contra adicciones
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
TW200806300A (en) New therapeutic combinations for the treatment of depression
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
GEAP202315801A (en) Antibacterial compounds
MY202884A (en) Compounds useful in hiv therapy
MX2024004725A (es) Metodos novedosos.
WO2021089768A3 (en) Treatment and prevention of a neurodegenerative disorder
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
MX2019006768A (es) Peptidos antimicrobianos.
MX2024006105A (es) Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme.
MX2021005944A (es) Inhibidores de rip1.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MX2021001335A (es) Inhibidores de ckd8/19.
MY205944A (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MX2020001199A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.